GLP-1
Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.
Sophia Umansky, the 26-year-old daughter of Kyle Richards, has undergone a breast lift. The procedure comes amid weight fluctuations from GLP-1 medications.
Ti AI ṣe iroyin
Scientists are launching a nationwide trial to evaluate whether the weight-loss drug Zepbound can alleviate long Covid symptoms. The study focuses on the drug's anti-inflammatory properties. Tirzepatide, Zepbound's active ingredient, has already shown benefits in reducing risks of cardiovascular and chronic kidney diseases beyond weight loss.